Relief Therapeutics Holding SA announced that its collaboration partner, ACER Therapeutics Inc. (Acer), has provided an update indicating that the commercial launch activities for OLPRUVA? (sodium phenylbutyrate) for oral suspension are progressing ahead of schedule.cer now reports the drug will be available in mid-June 2023, subject to additional capital. As a result of ongoing launch readiness efforts, Acer has reported it expects select OLPRUVA?
dose levels to be available to patients beginning in mid-June 2023 at which time representatives from Acer's patient support service will be available to begin accepting prescriptions. Acer anticipates publishing the OLPRUVA? list price, or wholesale acquisition cost (WAC), in mid-to-late May.